11/8
12:31 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/28
08:25 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/20
05:55 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was upgraded by analysts at HC Wainwright from a "hold" rating to a "strong-buy" rating.
9/16
10:55 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
9/16
10:55 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $7.00 price target on the stock.
9/16
10:12 am
prld
Rating for PRLD
Low
Report
Rating for PRLD
9/16
10:12 am
prld
Rating for PRLD
Low
Report
Rating for PRLD
9/16
08:03 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
9/10
08:01 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.